86910 Federal Register / Vol. 88, No. 240 / Friday, December 15, 2023 / Notices 

responsibilities in carrying out subpart 

II, part D of title III of the Public Health 

Service Act (42 U.S.C. 254d–254k), as 

amended, including the designation of 

areas of the United States with health 

professional shortages and assignment 

of National Health Service Corps 

(NHSC) clinicians to improve the 

delivery of health services in health 

professional shortage areas. 

Since priorities dictate meeting times, 

be advised that start times, end times, 

and agenda items are subject to change. 

For CY 2024 meetings, agenda items 

may include, but are not limited to, the 

identification of NHSC priorities for 

future program issues and concerns; 

proposed policy changes by using the 

varying levels of expertise represented 

on the NACNHSC to advise on specific 

program areas; updates from clinician 

workforce experts; and education and 

practice improvement in the training 

development of primary care clinicians. 

More general items may include 

presentations and discussions on the 

current and emerging needs of the 

health workforce, public health 

priorities, health care access and 

evaluation, NHSC-approved sites, HRSA 

priorities, and other federal health 

workforce and education programs that 

impact the NHSC. Refer to the 

NACNHSC website listed above for all 

current and updated information 

concerning the CY 2024 NACNHSC 

meetings. Agendas and meeting 

materials will be posted 30 calendar 

days before the meeting. 

Members of the public will have the 

opportunity to provide comments. 

Public participants may submit written 

statements in advance of the scheduled 

meeting(s). Oral comments will be 

honored in the order they are requested 

and may be limited as time allows. 

Requests to submit a written statement 

or make oral comments to NACNHSC 

should be sent to Diane Fabiyi-King 

using the contact information above at 

least 5 business days before the meeting 

date(s). 

Individuals who need special 

assistance or another reasonable 

accommodation should notify Diane 

Fabiyi-King using the contact 

information listed above at least 10 

business days before the meeting(s) they 

wish to attend. In-person meetings will 

occur in a federal government building, 

and attendees must go through a 

security check to enter the building. 

Non-U.S. Citizen attendees must notify 

Diane Fabiyi-King of their planned 

attendance at an in-person meeting at 

least 20 business days prior to the 

meeting to facilitate their entry into the 

building. All attendees are required to 

present government-issued 

identification prior to entry. 

Maria G. Button, 

Director, Executive Secretariat. 

[FR Doc. 2023–27604 Filed 12–14–23; 8:45 am] 

BILLING CODE 4165–15–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Health Resources and Services 

Administration 

Agency Information Collection 

Activities: Submission to OMB for 

Review and Approval; Public Comment 

Request; Maternal Health Portfolio 

Evaluation Design 

AGENCY: Health Resources and Services 

Administration (HRSA), Department of 

Health and Human Services. 

ACTION: Notice. 

SUMMARY: In compliance with the 

Paperwork Reduction Act of 1995, 

HRSA submitted an Information 

Collection Request (ICR) to the Office of 

Management and Budget (OMB) for 

review and approval. Comments 

submitted during the first public review 

of this ICR will be provided to OMB. 

OMB will accept further comments from 

the public during the review and 

approval period. OMB may act on 

HRSA’s ICR only after the 30-day 

comment period for this notice has 

closed. 

DATES: Comments on this ICR should be 

received no later than January 16, 2024. 

ADDRESSES: Written comments and 

recommendations for the proposed 

information collection should be sent 

within 30 days of publication of this 

notice to www.reginfo.gov/public/do/ 

PRAMain. Find this particular 

information collection by selecting 

‘‘Currently under Review—Open for 

Public Comments’’ or by using the 

search function. 

FOR FURTHER INFORMATION CONTACT: To 

request a copy of the clearance requests 

submitted to OMB for review, email 

Joella Roland, the HRSA Information 

Collection Clearance Officer, at 

paperwork@hrsa.gov or call (301) 443– 

3983. 

SUPPLEMENTARY INFORMATION: 

Information Collection Request Title: 

Maternal Health Portfolio Evaluation 

Design OMB No. 0906–0059—Revision. 

Abstract: HRSA programs provide 

health care to people who are 

geographically isolated, economically, 

or medically vulnerable. HRSA 

programs help those in need of highquality primary health care, such as 

pregnant women and mothers. 

Improving maternal health outcomes 

and access to quality maternity care 

services is a key component of the 

HRSA mission. HRSA’s Maternal and 

Child Health Bureau provides funding 

to address some of the most urgent 

issues influencing the high rates of 

maternal mortality. With this emphasis 

on improving maternal health across the 

life course and promoting optimal 

health for all mothers, HRSA is 

employing a multipronged strategy to 

address maternal mortality and severe 

maternal morbidity through the 

following suite of programs: 

1. The State Maternal Health 

Innovation Program, 

2. The Alliance for Innovation on 

Maternal Health Program, 

3. The Alliance for Innovation on 

Maternal Health—Community Care 

Initiative, 

4. The Rural Maternity and Obstetrics 

Management Strategies Program, and 

5. The Supporting Maternal Health 

Innovation Program. 

HRSA’s Maternal and Child Health 

Bureau is conducting a portfolio-wide 

evaluation of HRSA-supported maternal 

health programs with a primary focus 

on reducing maternal mortality. 

Through this evaluation, HRSA seeks to 

identify individual and/or collective 

strategies, interrelated activities, and 

common themes within and across the 

maternal health programs that may be 

contributing to or driving improvements 

in key maternal health outcomes. HRSA 

seeks to ascertain which components 

should be elevated and replicated to the 

national level, as well as inform future 

investments to reduce rates of maternal 

mortality and severe maternal 

morbidity. 

A 60-day notice published in the 

Federal Register on September 18, 2023, 

88 FR 63965–66. There were three 

public comments received. Two 

comments were informational and did 

not require changes and one comment 

was a request for more information, 

which was provided. 

Need and Proposed Use of the 

Information: HRSA seeks to understand 

the impact of HRSA’s investments into 

maternal health programs. These five 

HRSA maternal health programs 

represent a total of 12 state-based 

grantees and three grantees with the 

potential for national reach. In 

understanding the strategies that are 

most effective in reducing maternal 

morbidity and mortality, HRSA will be 

able to determine which program 

elements could be replicated and/or 

scaled up nationally. 

Likely Respondents: Likely 

respondents are recipients of the 


ddrumheller on DSK120RN23PROD with NOTICES1
Federal Register / Vol. 88, No. 240 / Friday, December 15, 2023 / Notices 86911 

cooperative agreements mentioned 

above (State Maternal Health Innovation 

Program, Alliance for Innovation on 

Maternal Health Program, Alliance for 

Innovation on Maternal Health— 

Community Care Initiative, and 

Supporting Maternal Health Innovation 

Program) which include state health 

agencies, national organizations, and 

academic organizations. 

Burden Statement: Burden in this 

context means the time expended by 

persons to generate, maintain, retain, 

disclose, or provide the information 

requested. This includes the time 

needed to review instructions; to 

develop, acquire, install, and utilize 

technology and systems for the purpose 

of collecting, validating, and verifying 

information, processing and 

maintaining information, and disclosing 

and providing information; to train 

personnel and to be able to respond to 

a collection of information; to search 

data sources; to complete and review 

the collection of information; and to 

transmit or otherwise disclose the 

information. The total annual burden 

hours estimated for this ICR are 

summarized in the table below. 

TOTAL ESTIMATED ANNUALIZED BURDEN HOURS

Form name Number of 

respondents 

Number of 

responses per 

respondent 

Total 

responses 

Average 

burden per 

response 

(in hours) 

Total 

burden 

hours 

Instrument 1: Interview guide for grantee staff ................................ 60 1.0 60 1.125 67.50 

Instrument 2: Interview guide for HRSA Project Officers ................ 7 1.0 7 1.500 10.50 

Instrument 3: Partnership Survey .................................................... 290 0.5 145 0.250 36.25 

Instrument 4: Web-based data collection tool ................................. 12 1.0 12 0.500 6.00 

Total .......................................................................................... 369 ........................ 224 ........................ 120.25 

Maria G. Button, 

Director, Executive Secretariat. 

[FR Doc. 2023–27567 Filed 12–14–23; 8:45 am] 

BILLING CODE 4165–15–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute on Drug Abuse; 

Notice of Closed Meetings 

Pursuant to section 1009 of the 

Federal Advisory Committee Act, as 

amended, notice is hereby given of the 

following meetings. 

The meetings will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Institute on 

Drug Abuse Special Emphasis Panel; 

Addressing Racial Equity in Substance Use 

and Addiction Research Through 

Community-Engaged Research. 

Date: January 30, 2024. 

Time: 12:00 p.m. to 3:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institute of Health, 

National Institute on Drug Abuse, 301 North 

Stonestreet Avenue, Bethesda, MD 20892 

(Virtual Meeting). 

Contact Person: Sindhu Kizhakke 

Madathil, Ph.D., Scientific Review Officer, 

Division of Extramural Research, Scientific 

Review Branch, National Institute on Drug 

Abuse, NIH, 301 North Stonestreet Avenue, 

MSC 6021, Bethesda, MD 20892, (301) 827– 

5702, sindhu.kizhakkemadathil@nih.gov. 

Name of Committee: National Institute on 

Drug Abuse Special Emphasis Panel; Patient 

Engagement Resource Centers to Inform SUD 

Treatment Services Research. 

Date: January 31, 2024. 

Time: 11:00 a.m. to 4:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institute of Health, 

National Institute on Drug Abuse, 301 North 

Stonestreet Avenue, Bethesda, MD 20892 

(Virtual Meeting). 

Contact Person: Shareen Iqbal, Ph.D., 

Scientific Review Officer, Scientific Review 

Branch, Division of Extramural Research, 

National Institute on Drug Abuse, NIH, 301 

North Stonestreet Avenue, MSC 6021, 

Bethesda, MD 20892, (301) 443–4577, 

shareen.iqbal@nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.277, Drug Abuse Scientist 

Development Award for Clinicians, Scientist 

Development Awards, and Research Scientist 

Awards; 93.278, Drug Abuse National 

Research Service Awards for Research 

Training; 93.279, Drug Abuse and Addiction 

Research Programs, National Institutes of 

Health, HHS) 

Dated: December 11, 2023. 

Lauren A. Fleck, 

Program Analyst, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2023–27540 Filed 12–14–23; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute on Alcohol Abuse 

and Alcoholism; Notice of Closed 

Meetings 

Pursuant to section 1009 of the 

Federal Advisory Committee Act, as 

amended, notice is hereby given of the 

following meetings. 

The meetings will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Institute on 

Alcohol Abuse and Alcoholism Initial 

Review Group; Epidemiology, Prevention 

and Behavior Research Study Section. 

Date: February 27, 2024. 

Time: 9:30 a.m. to 5:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institute of Health, 

National Institute on Alcohol Abuse and 

Alcoholism, 6700B Rockledge Drive, 

Bethesda, MD 20892 (Virtual Meeting). 

Contact Person: Anna Ghambaryan, M.D., 

Ph.D., Scientific Review Officer, Extramural 

Project Review Branch, Office of Extramural 

Activities, National Institute on Alcohol 

Abuse and Alcoholism, 6700B Rockledge 

Drive, Room 2120, MSC 6902, Bethesda, MD 

20892, 301–443–4032, anna.ghambaryan@

nih.gov. 


ddrumheller on DSK120RN23PROD with NOTICES1